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Abstract:  Our  understanding
underlying the disease process in patients with thalassaemia intermedia (TI) has substantially 
increased over the past decade. 
phenotypes.  Some TI  patients  are  asymptomatic  until  adult  life,  whereas  others  are 
symptomatic from as young as 2 years of age. A number of clinical complications commonly 
associated  with  TI  are  rarely  seen  in  thalassaemia  major,  including  extramedullary 
hematopoiesis, leg ulcers, gallstones, thrombosis and pulmonary hypertension. 
number of options currently available for managing patients with TI, including transfusion 
therapy,  iron  chelation  therapy,  modulation  of  foetal  haemoglobin  production  and 
haematopoietic stem cell transplantation. However, a
for an orchestrated optimal treatment plan. 
Introduction: Thalassaemia  was  defined  as  a 
clinical entity in 1925 by Dr. Thomas B. Cooley at 
the  annual  meeting  of  the  American  Pediatric 
Society  where  he  presented  five  young  children 
with  severe  anaemia,  splenomegaly, 
bone  abnormalities
1.  Almost  all  pat
thalassaemia  syndromes  were  later  classified  as 
having  thalassaemia  minor  or  thalassaemia  major 
(TM). However, a small number of patients did not 
fit into this categorical distribution. Sturgeon was 
the  first  to  describe  this  group  in  the  Amer
literature.  He  suggested  the  term  thalassaemia 
intermedia (TI) to describe patients who had clinical 
manifestations  that  are  too  severe  to  be  termed 
; Open Journal System 
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Our  understanding of  the  molecular  and  pathophysiological  mechanisms 
underlying the disease process in patients with thalassaemia intermedia (TI) has substantially 
increased over the past decade. TI encompasses a wide clinical spectrum of beta
TI  patients  are  asymptomatic  until  adult  life,  whereas  others  are 
symptomatic from as young as 2 years of age. A number of clinical complications commonly 
associated  with  TI  are  rarely  seen  in  thalassaemia  major,  including  extramedullary 
g ulcers, gallstones, thrombosis and pulmonary hypertension. 
number of options currently available for managing patients with TI, including transfusion 
therapy,  iron  chelation  therapy,  modulation  of  foetal  haemoglobin  production  and 
tic stem cell transplantation. However, at present, there are no clear guidelines 
for an orchestrated optimal treatment plan. 
Thalassaemia  was  defined  as  a 
clinical entity in 1925 by Dr. Thomas B. Cooley at 
the  annual  meeting  of  the  American  Pediatric 
Society  where  he  presented  five  young  children 
with  severe  anaemia,  splenomegaly,  and  peculiar 
.  Almost  all  patients  with  β-
thalassaemia  syndromes  were  later  classified  as 
having  thalassaemia  minor  or  thalassaemia  major 
However, a small number of patients did not 
fit into this categorical distribution. Sturgeon was 
the  first  to  describe  this  group  in  the  American 
literature.  He  suggested  the  term  thalassaemia 
intermedia (TI) to describe patients who had clinical 
manifestations  that  are  too  severe  to  be  termed 
minor and too mild to be termed major
our  knowledge  of  the  molecular  basis  and 
pathophysiology of TI has progressed significantly 
in  the  last  decade,  including  an  increased 
understanding of the genetic mutations
the TI phenotypes
3,4. The clinical presentation and 
sequelae of TI span  a  wide  spectrum  of  severity. 
The  natural  history  of  the  disease  allows  the 
emergence  of  several  complications  that  are 
relatively unique to TI compared to TM
the optimal course of management for TI patients 
has been hard to identify and several controversies 
remain  regarding  the  best  treatm
review  summarizes  molecular  and  clinical 
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of  the  molecular  and  pathophysiological  mechanisms 
underlying the disease process in patients with thalassaemia intermedia (TI) has substantially 
TI encompasses a wide clinical spectrum of beta-thalassaemia 
TI  patients  are  asymptomatic  until  adult  life,  whereas  others  are 
symptomatic from as young as 2 years of age. A number of clinical complications commonly 
associated  with  TI  are  rarely  seen  in  thalassaemia  major,  including  extramedullary 
g ulcers, gallstones, thrombosis and pulmonary hypertension. There are a 
number of options currently available for managing patients with TI, including transfusion 
therapy,  iron  chelation  therapy,  modulation  of  foetal  haemoglobin  production  and 
t present, there are no clear guidelines 
and too mild to be termed major
2. Ever since, 
our  knowledge  of  the  molecular  basis  and 
iology of TI has progressed significantly 
in  the  last  decade,  including  an  increased 
understanding of the genetic mutations that lead to 
. The clinical presentation and 
sequelae of TI span  a  wide  spectrum  of  severity. 
y  of  the  disease  allows  the 
emergence  of  several  complications  that  are 
ely unique to TI compared to TM
5. As such, 
the optimal course of management for TI patients 
has been hard to identify and several controversies 
remain  regarding  the  best  treatment  plan
6.  This 
review  summarizes  molecular  and  clinical Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
characteristics of TI. Moreover, currently practiced 
treatment  options  and  insights  onto  future 
perspectives are discussed.  
Molecular  Understanding. The  clinical 
manifestations of thalassaemia result from defects 
in  one  of  two  types  of  haemoglobin  (Hb) 
polypeptide  chains  (alpha  or  beta).  For  Hb  to 
function properly, the number of alpha-chains must 
precisely  match  the  number  of  beta-chains; 
thalassaemia is caused by an imbalance in globin 
chain  synthesis. The  beta-thalassaemias, including 
TI, arise from defective gene function leading to the 
partial  suppression  of  beta-globin  protein 
production. The extent of suppression varies from 
patient to patient and dictates the clinical severity of 
disease.  Most  TI  patients  are  homozygotes  or 
compound  heterozygotes  for  beta-thalassaemia, 
meaning  that  both  beta-globin  loci  are  affected
3. 
Less commonly, only a single beta-globin locus is 
affected, the other being completely normal.
1 The 
mild  clinical  characteristics  of  TI  compared  with 
TM  major  result  primarily  from  three  different 
mechanisms:
3,7
•  Inheritance  of  a  mild  or  silent  beta-chain 
mutation. Rather than a complete absence of beta-
chain synthesis, the level of synthesis is subnormal. 
This  leads  to  a  smaller  imbalance  between  the 
number of alpha-and beta-chains compared with an 
absence of beta-chains.
•  Co-inheritance  of  determinants  associated 
with  increased  gamma-chain  production.  The 
increased  number  of  gamma-chains  helps  to 
neutralize the  large proportion  of  unbound alpha-
chains.
•  Co-inheritance  of  alpha-thalassaemia.  This 
helps  to  suppress  the  synthesis  of  alpha-chains, 
causing less of an alpha/beta-chain imbalance. 
The  phenotype  of  TI  may  result  from  the 
increased  production  of  alpha-globin  chains  by  a 
triplicated  or  quadruplicated  alpha  genotype 
associated  with  beta-heterozygosity.
8-10 Table  1
shows β-globin mutations in TI and TM that have a 
direct  effect  on  modifying  the  amount  of  excess 
alpha-chains,  such  as  inheritance  of  abnormal 
alpha- or  gamma-chain  genes.  Tertiary  modifiers 
are  polymorphisms  occurring  at  loci  involved  in 
bone,  iron  and  bilirubin  metabolism  which  can 
affect  clinical  expression,  although  these  are 
thought to be of relatively little importance. Recent 
studies  of  the  JAK2  cytoplasmic  tyrosine  kinase, 
which has a vital role in signal transduction from 
several  haemopoietic  growth  factor  receptors, 
revealed a V617F mutation that was implicated in a 
variety  of  diseases  mainly  related  to  myelo-
proliferative  disorders  including  polycythaemia 
vera,  essential  thrombocythaemia,  and  idiopathic 
myelofibrosis.  TI  patients,  however,  do  not  show 
increased expression of this mutation.
11
Table  1. Prevalent  beta-globin  mutations  in  thalassaemia 
intermedia and thalassaemia major in patients of Mediterranean 
origin.
7
Mutation
Thalassemia 
Intermedia 
Thalassemia 
major 
n(%) n(%)
cd 39 C->T 72 (24) 136 (53.5)
IVSI-110 G->T 52 (17) 58 (23)
IVSI-6 T->C 94 (31.5) 16 (6.3)
IVSI-1 G->A 8 (2.7) 19 (7.4)
IVSII-1 G->A 14 (4.7) 10 (3.9)
IVSII-745 C->G 11 (3.7) 9 (3.5)
-101 C->T 10(3.3) -
cd6 - A 10(3.3) 3 (1.2)
-87 C->G 8 (2.7) -
Siciliana 13 (4.3) -
Lepore Boston 2 (0.7) -
IVSI-5 G->A - 1 (0.4)
IVSI-5 G->C 1 (0.3) -
IVSII-844 G->C 1 (0.3) -
IVSI-2 T->A 1 (0.3) -
cd 44 - C - 1 (0.4)
cd 8 - AA 1 (0.3) 1 (0.4)
Total 298 (100) 254 (100)
Environmental  factors  including  social 
conditions, nutrition and the availability of medical 
care have also been implicated as key players in the 
phenotypic variability of TI.
12
A number of studies have attempted to classify 
patients with TI according to the severity of their 
condition,  although  these  studies  have  had  only 
limited  success.
13,14 A  recent  study  described  the 
development  of  a  phenotype  scoring  system  that 
successfully  sub-classified  TI  patients  into  three 
separate groups: mild, moderate or severe 
15. The 
severity of TI was graded according to a number of 
clinical  features,  such  as  age  at  presentation, 
severity  of  anaemia,  extent  of  growth  retardation 
and  bone  marrow  hyperplasia,  blood  transfusion 
requirements  and  need  for  splenectomy.  This 
classification  could  prove  useful  for  relating 
genotype to phenotype and for developing separate 
treatment guidelines for different disease severities.Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 2. Criteria to differentiate thalassaemia major from intermedia at presentation.
Parameter Thalassaemia major
more likely
Thalassaemia intermedia
more likely
Clinical
Presentation (years) <2 >2
Liver/spleen enlargement Severe Moderate to severe
Haematological
Hb level (g/dL) 6–7 7–10
HbF (%) >50 10–50 (may be up to 100%)
HbA2 (%) <3.5 >3.5
Genetic
Parents Both carriers of high HbA2
β-thalassaemia
One or both atypical carriers:
– High HbF β-thalassaemia
– Borderline HbA2
Molecular
Type of mutation Severe Mild/silent
Co-inheritance of α-thalassaemia No Yes
Hereditary persistence of HbF No Yes
δβ-thalassaemia No Yes
Gγ Xmn1 polymorphism No Yes
Hb = haemoglobin; HbF = foetal haemoglobin
However,  further  studies  would  be  required  to 
confirm the reliability and utility of this approach. 
Although  the  clinical  phenotypes  of 
thalassaemia  minor,  intermedia  and  major  differ, 
there are some similarities. There is an increasing 
awareness  of  the  need  for  accurate  diagnosis  in 
order to achieve optimal patient management and to 
avoid  over  or  under  treatment
3,16.  The  accurate 
identification of TI versus thalassaemia minor and 
TM can be difficult if based on clinical presentation 
alone,  although  certain  differentiating  parameters 
have  been  established.  In  general,  TI  is 
characterized by Hb levels maintained around 7–10 
g/dL  without  the  need  for  regular  blood 
transfusions, by more severe red blood cell (RBC) 
abnormalities than thalassaemia minor, by a varying 
degree  of  spleen  enlargement,  and  by  skeletal 
changes such as expansion of the facial bones and 
obliteration of the maxillary sinuses, which causes 
protrusion  of  the  upper  jaw.
5,6,16 Criteria  for 
differentiating  TM  from  TI  at  presentation  are 
summarised in Table 2.
Pathophysiology. Three  main  factors  are 
responsible  for  the  clinical  manifestations  of  TI: 
ineffective  erythropoiesis,  chronic  haemolytic 
anaemia and iron overload. The severity of clinical 
sequelae  primarily  depends  on  the  underlying 
molecular defects. Alpha-chains are highly unstable 
and  precipitate  within  erythroid  precursors  in  the 
bone marrow, causing membrane damage and cell 
death  – this  is  ineffective  erythropoiesis.
17
Hypertrophy of erythroid marrow in medullary and 
extramedullary  sites,  a  consequence  of  severe 
ineffective  erythropoiesis,  results  in  characteristic 
deformities of the skull and face and may also cause 
cortical thinning and pathological fractures of long 
bones.
16,18 The degree of ineffective erythropoiesis 
is the primary determinant of the development of 
anaemia,  while  peripheral  haemolysis  of  mature 
RBCs and an overall reduction in Hb synthesis are 
secondary.  However,  haemolysis  per  se  has  been 
linked  to  the  development  of  a  hypercoagulable 
state  and  pulmonary  hypertension  (PHT)  in  this 
patient  population.
19,20 Damaged  circulating  RBCs 
expose  negatively  charged  phosphatidyl-serine 
residues  through  the  ‘Flip-Flop’  phenomenon.
21
These along with activation of platelets, endothelial 
cells and monocytes along with dysfunction of the 
coagulation  system  have  been  associated  with 
thromboembolic  phenomenon,  especially  in 
splenectomised TI patients
21. Moreover, haemolysis 
carries  a  role  in  the  dysregulation  of  nitric  oxide 
(NO) homeostasis which is correlated with PHT and 
probably thrombotic phenomena (Figure 1).
22
In contrast to patients with TM, in whom iron 
loading  occurs  mainly  as  a  result  of  transfusion 
therapy, patients with TI accumulate iron primarily Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 1. Nitric oxide dependent pathway leading to pulmonary hypertension and, 
intermedia patients (Hb = haemoglobin, RBC = red blood cell, PHT = pulmonary hypertension, VCAM = vascular cell adhesion 
molecule).
due  to  increased  intestinal  iron  absorption.
chronic anaemia and ineffective erythropoiesis that 
are characteristic of TI are associated with reduced 
expression of hepcidin, a hepatic peptide that plays 
a central role in iron homeostasis.
23
indicate  that  growth  and  differentiation  factor  15 
(GDF15),  secreted  by  erythroid  precursors,  is 
significantly  increased  in  patients  with  TM, 
inhibiting hepcidin production.
24 In addition, other 
studies indicate that hypoxia-inducible transcription 
factors  (HIFs) control  iron  homeostasis  by 
coordinating  the  downregulation  of  hepcidin  and 
the upregulation of erythropoietin and ferroportin. 
Under normal conditions, HIFs play a useful role by 
mobilizing  iron  and  supporting  erythrocyte 
production  in  response  to  anaemi
However, the  same mechanism  may contribute  to 
the harmful accumulation of iron in response to the 
chronic  anaemia  of  TI.  The  combination 
ineffective  erythropoiesis  (leading  to  increased 
GDF15) and chronic anaemia/hypoxia (altering the 
expression of HIF) results in hepcidin suppression, 
; Open Journal System 
Nitric oxide dependent pathway leading to pulmonary hypertension and, possibly, thrombotic phenomena in thalassaemia 
intermedia patients (Hb = haemoglobin, RBC = red blood cell, PHT = pulmonary hypertension, VCAM = vascular cell adhesion 
due  to  increased  intestinal  iron  absorption.
23 The 
chronic anaemia and ineffective erythropoiesis that 
are characteristic of TI are associated with reduced 
expression of hepcidin, a hepatic peptide that plays 
23 Recent studies 
indicate  that  growth  and  differentiation  factor  15 
(GDF15),  secreted  by  erythroid  precursors,  is 
significantly  increased  in  patients  with  TM, 
In addition, other 
inducible transcription 
control  iron  homeostasis  by 
coordinating  the  downregulation  of  hepcidin  and 
the upregulation of erythropoietin and ferroportin. 
Under normal conditions, HIFs play a useful role by 
mobilizing  iron  and  supporting  erythrocyte 
production  in  response  to  anaemia/hypoxia.
25-27
However, the  same mechanism  may contribute  to 
the harmful accumulation of iron in response to the 
chronic  anaemia  of  TI.  The  combination  of 
ineffective  erythropoiesis  (leading  to  increased 
GDF15) and chronic anaemia/hypoxia (altering the 
expression of HIF) results in hepcidin suppression, 
increased iron absorption and increased release of 
recycled  iron  from  the  reticuloendothelial  (RE) 
system.  This  results  in  depletion  of  macrophage 
iron, and relatively low levels of serum ferritin. The 
situation in TI is similar to that seen in patients with 
hereditary  hemochromatosis  syndromes,  which  is 
characterized  by  impaired  hepcidin  production 
(Figure 2). 
By contrast, in transfused TM patients iron is 
preferentially  distributed  to  the  RE  system, 
stimulating ferritin synthesis and its release to the 
circulation  and  leading  to  high  serum  ferritin 
levels
28.  Blood  transfusions  modify  hepcidin 
production by altering all three factors responsible 
for the clinical manifestations of TI described above 
namely:  (i)  by  correcting 
therapy will suppress ineffective erythropoiesis and 
the associated increase in GDF15; (ii) by correcting 
anaemia,  blood  transfusions  will  prevent  the 
hypoxia  responsible  for  increased  HIF  production 
and  hypoxia-associated  suppression 
and  (iii)  increased  body  iron  and  transferrin 
possibly, thrombotic phenomena in thalassaemia 
intermedia patients (Hb = haemoglobin, RBC = red blood cell, PHT = pulmonary hypertension, VCAM = vascular cell adhesion 
increased iron absorption and increased release of 
recycled  iron  from  the  reticuloendothelial  (RE) 
em.  This  results  in  depletion  of  macrophage 
iron, and relatively low levels of serum ferritin. The 
situation in TI is similar to that seen in patients with 
hereditary  hemochromatosis  syndromes,  which  is 
characterized  by  impaired  hepcidin  production 
By contrast, in transfused TM patients iron is 
preferentially  distributed  to  the  RE  system, 
stimulating ferritin synthesis and its release to the 
circulation  and  leading  to  high  serum  ferritin 
.  Blood  transfusions  modify  hepcidin 
production by altering all three factors responsible 
for the clinical manifestations of TI described above 
namely:  (i)  by  correcting  anaemia,  transfusion 
therapy will suppress ineffective erythropoiesis and 
the associated increase in GDF15; (ii) by correcting 
anaemia,  blood  transfusions  will  prevent  the 
hypoxia  responsible  for  increased  HIF  production 
associated  suppression  of  hepcidin; 
and  (iii)  increased  body  iron  and  transferrin Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Figure 2. Pathophysiology of iron overload in patients with thalassaemia intermedia. GDF15 = growth differentiation factor 15; HIF 
=  hypoxia-inducible  transcription  factor;  RES  = 
concentration.
saturation will stimulate hepcidin production. The 
result  will  be  a  relative  increase  in  hepcidin 
production  in  polytransfused  TM  patients 
countering  the  hepcidin-inhibitory  effects  of 
anaemia  and  ineffective  erythropoiesis.  These 
considerations may explain the differences in iron 
homeostasis  characterizing  TM  compared  with 
untransfused TI patients. Thus, although the rate of 
iron  loading  may  be  slower  than  that  in  patients 
with  TM,  TI  patients  will  inevitably  suffer  from 
iron overload which in turn can cause a number of 
serious complications including cardiac failure and 
endocrine  abnormalities  such  as  diabetes  mellitus 
and hypogonadism.
Clinical  Sequelae. As  a  consequence  of  the 
aforementioned  pathophysiology,  several 
complications have been identified in patients with 
TI. Some of these complications have been termed 
unique to TI as compared to TM, especially in the 
splenectomised, transfusion naïve pa
Cholelithiasis Gallstones are much more common 
in  TI  than  in  TM  because  of  ineffective 
erythropoiesis and peripheral haemolysis. Recently, 
unrelated  genetic  factors  such  as  uridine  5’
diphospho-alpha-D-glucose  (UDPG)  deficiency 
(Gilbert’s syndrome) have been reported to increase 
gallstone formation in patients with thalassaemia
For this reason, the gallbladder should be inspected 
during  splenectomy  and  a  cholecystectomy 
performed if necessary, particularly if the patient is 
experiencing  symptomatic  gallstones.  This  should 
be  undertaken to  prevent cholecystitis, which can 
; Open Journal System 
Pathophysiology of iron overload in patients with thalassaemia intermedia. GDF15 = growth differentiation factor 15; HIF 
inducible  transcription  factor;  RES  =  reticuloendothelial  system;  VHL  =    von  Hippel
saturation will stimulate hepcidin production. The 
result  will  be  a  relative  increase  in  hepcidin 
production  in  polytransfused  TM  patients 
inhibitory  effects  of 
anaemia  and  ineffective  erythropoiesis.  These 
considerations may explain the differences in iron 
homeostasis  characterizing  TM  compared  with 
untransfused TI patients. Thus, although the rate of 
than  that  in  patients 
with  TM,  TI  patients  will  inevitably  suffer  from 
iron overload which in turn can cause a number of 
serious complications including cardiac failure and 
endocrine  abnormalities  such  as  diabetes  mellitus 
As  a  consequence  of  the 
aforementioned  pathophysiology,  several 
complications have been identified in patients with 
TI. Some of these complications have been termed 
unique to TI as compared to TM, especially in the 
splenectomised, transfusion naïve patient (Table 3).
Gallstones are much more common 
in  TI  than  in  TM  because  of  ineffective 
erythropoiesis and peripheral haemolysis. Recently, 
unrelated  genetic  factors  such  as  uridine  5’-
glucose  (UDPG)  deficiency 
syndrome) have been reported to increase 
gallstone formation in patients with thalassaemia
29. 
For this reason, the gallbladder should be inspected 
during  splenectomy  and  a  cholecystectomy 
performed if necessary, particularly if the patient is 
symptomatic  gallstones.  This  should 
be  undertaken to  prevent cholecystitis, which can 
have  serious  consequences  in  the  splenectomised 
patient.
Extramedullary  haematopoiesis
haematopoiesis  (EMH)  is  a  compensatory 
mechanism  where  bone marrow
in an attempt to overcome the chronic anaemia of 
TI, leading to the formation of erythropoietic tissue 
masses  that  primarily  affect  the  spleen,  liver  and 
lymph  nodes.  These  masses  can  be  detected  by 
magnetic  resonance  imaging  (MRI).  The
cause  neurological  problems  such  as  spinal  cord 
compression  and  paraplegia,  and  intrathoracic 
masses.
30,31 Extramedullary haemato
managed  by  radiotherapy  (since  haematopoietic 
tissue is highly radiosensitive)
or hydroxyurea.
30,33,34
Leg ulcers. Leg ulcers are more common in older 
than in younger patients with TI. It is unclear why 
ulcers develop in some patients who are maintained 
at  relatively  low  Hb  levels  and  have  the  same 
amount of foetal Hb (HbF) as others in
do  not  develop.  The  skin  at  the  extremities  of 
elderly TI patients can be thin due to reduced tissue 
oxygenation,  and  this  makes  the  subcutaneous 
tissue fragile and increases the risk of lesions from 
minimal  trauma.  Once  an  ulcer  has  started  t
develop  it  is  very  painful  and  difficult  to  cure, 
although  regular  blood  transfusions  may  provide 
some  relief  in  persistent  cases.  Simple  measures 
may be beneficial, such as keeping the patient’s legs 
and feet raised above the level of the heart for 1
hours during the day or sleeping with the end of the 
bed  raised.  Zinc  supplementation
pentoxifylline, which alters the rheological 
Pathophysiology of iron overload in patients with thalassaemia intermedia. GDF15 = growth differentiation factor 15; HIF 
reticuloendothelial  system;  VHL  =    von  Hippel-Lindau;  LIC  =  liver  iron 
have  serious  consequences  in  the  splenectomised 
Extramedullary  haematopoiesis. Extra-medullary 
haematopoiesis  (EMH)  is  a  compensatory 
mechanism  where  bone marrow activity increases 
in an attempt to overcome the chronic anaemia of 
TI, leading to the formation of erythropoietic tissue 
masses  that  primarily  affect  the  spleen,  liver  and 
lymph  nodes.  These  masses  can  be  detected  by 
magnetic  resonance  imaging  (MRI).  They  may 
cause  neurological  problems  such  as  spinal  cord 
compression  and  paraplegia,  and  intrathoracic 
Extramedullary haemato-poiesis can be 
managed  by  radiotherapy  (since  haematopoietic 
tissue is highly radiosensitive)
32, transfusion therapy 
Leg ulcers are more common in older 
than in younger patients with TI. It is unclear why 
ulcers develop in some patients who are maintained 
at  relatively  low  Hb  levels  and  have  the  same 
amount of foetal Hb (HbF) as others in whom ulcers 
do  not  develop.  The  skin  at  the  extremities  of 
elderly TI patients can be thin due to reduced tissue 
oxygenation,  and  this  makes  the  subcutaneous 
tissue fragile and increases the risk of lesions from 
minimal  trauma.  Once  an  ulcer  has  started  to 
develop  it  is  very  painful  and  difficult  to  cure, 
although  regular  blood  transfusions  may  provide 
some  relief  in  persistent  cases.  Simple  measures 
may be beneficial, such as keeping the patient’s legs 
and feet raised above the level of the heart for 1–2 
hours during the day or sleeping with the end of the 
bed  raised.  Zinc  supplementation
35 and 
pentoxifylline, which alters the rheological Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
Table 3. Prevalence of complications in thalassaemia intermedia vs. major.
5
Complication 
(% of patients affected)
Thalassaemia intermedia Thalassaemia major
Lebanon Italy Lebanon Italy
(n = 37) (n = 63) (n = 40) (n = 60)
Splenectomy 90 67 95 83
Cholecystectomy 85 68 15 7
Gallstones 55 63 10 23
Extramedullary haemopoiesis 20 24 0 0
Leg ulcers 20 33 0 0
Thrombotic events 28 22 0 0
Cardiopathy* 3 5 10 25
Pulmonary hypertension
† 50 17 10 11
Abnormal liver enzymes 20 22 55 68
HCV infection 7 33 7 98
Hypogonadism 5 3 80 93
Diabetes mellitus 3 2 12.5 10
Hypothyroidism 3 2 15 11
*Fractional shortening < 35%. †Defined as pulmonary artery systolic pressure > 30 mmHg; a well-enveloped tricuspid regurgitant 
jet velocity could be detected in only 20 patients, so frequency was assessed in these patients only.
properties  of  the  RBCs,
36 can  help  accelerate the 
healing  of  ulcers.  Hydroxyurea  also  has  some 
benefit,  either  alone  or  in  combination  with 
erythropoietin.
37 In addition, the use of an oxygen 
chamber  can  provide  moderate  relief  since  tissue 
hypoxia  may  be  an  underlying  cause  of  the 
ulceration.
38
Thromboembolic events. Taher et al.
39 analyzed data 
from  8860  thalassaemia  patients  (6670  TM  and 
2190  TI).  In  this  study  thromboembolic  events 
(TEE)  occurred 4.38 times more frequently in TI 
than  TM  patients,  with  more  venous  events 
occurring in TI and more arterial events occurring 
in TM. In another series of TI patients, 24 patients 
(29%)  developed  either  deep  vein  thrombosis 
(DVT),  pulmonary  embolism,  or  portal  vein 
thrombosis during a 10-year follow up.
40In a recent 
survey involving nine Italian pediatric thalassaemia 
centres, TEE was observed in 4% of 683 patients 
with  TM  and  in  9.6%  of  52  patients  with  TI.
41
Studies collectively revealed that the incidence of 
TEE is  higher in  splenectomised patients.
39,40 The 
incidence  of  overt  stroke  in  TI  patients  is  low;
8
however,  a  study  done  to  assess  the  rate  of 
asymptomatic brain damage in patients with benign 
haemoglobinopathies  reported  that  37.5%  of 
patients with TI showed silent brain ischemia.
42
Pulmonary  hypertension  and  congestive  heart 
failure. Pulmonary hypertension (PHT) is prevalent 
in patients with TI (59.1%),
20 and is thought to be 
the primary cause of congestive heart failure in this 
patient population. A retrospective analysis showed 
that  splenectomised  females  with  significant 
anaemia,  thrombocytosis  and  elevated  ferritin 
levels, were at greatest risk for developing PHT.
43
Preliminary results have demonstrated that PHT is 
reversible by blood transfusion and treatment with 
aspirin  and  warfarin.  Several  echocardiographic 
studies have confirmed that cardiac ejection fraction 
is rarely affected in TI.
44 Nevertheless, patients with 
TI often have an increased cardiac output, and left 
ventricular  wall  dimensions  proportional  to  the 
dilutional  volume  overload  secondary  to  chronic 
anaemia.
45
As anaemia and iron overload are uncommon in 
well-transfused and chelated TM patients, they are 
likely to be at the heart of the pathophysiology of 
PHT.  A  recent  study  demonstrated  a  significant 
correlation  between  iron  overloading  in  the  liver 
and pulmonary artery systolic pressure independent Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
of  left  ventricular  filling  pressures.
46 Regular 
transfusion and iron chelation therapy is therefore 
indicated  in  TI  patients  who  are  well-stratified 
according  to  the  early  detection  of  PHT  indices. 
Sildenafil has also been successfully used to treat 
PHT,
47 although  data  from  large  patient  numbers 
are lacking in TI.
Pregnancy and related complications. Women with 
TI  may  have  spontaneous  successful  pregnancies 
although  complications  during  pregnancy  may 
occur
48. The  chronic anaemia  of  TI can  cause  an 
increase in spontaneous abortions, pre-term labour 
and intrauterine growth retardation, while endocrine 
complications  due  to  haemo-siderosis  are 
common
49.  The  course  and  outcome  of  19 
pregnancies  was  assessed  in  16  women  with 
thalassaemia,  including  four  with  TI
50.  All 
pregnancies were uneventful and elective Caesarean 
section was performed in each case. The mean birth 
weight  of  the  babies  was  3000  g  and  all  were 
normal  except  for  one  case of  omphalocele.  The 
largest study to date assessed 44 TI women who had 
83 pregnancies, all spontaneous, 30 from Lebanon 
and 53 from Italy.
51 These pregnancies resulted in 
20.5%  abortions,  77.1%  live-births  and  2 
intrauterine  foetal  deaths  at  26  and  36  weeks’ 
gestation. The mean gestational age at delivery was 
36.5 weeks and mean birth weight was 2551 g. In 
pregnancies progressing > 20 weeks’ gestation, pre-
term  delivery  and  intrauterine  growth  restriction 
(IUGR) were noted in 31.8% and 24.2% of cases, 
respectively.  In  those  complicated  by  IUGR, 
Caesarean  delivery  (CS)  rate  was  87.5%.  Two 
women  (Italy)  developed  severe  alloimmune 
haemolytic  anaemia.  One  progressed  to  cardiac 
failure  at  35  weeks’  gestation  and  had  CS.  The 
other underwent CS for IUGR and non-reassuring 
foetal  heart  monitoring  and  was  scheduled  for  a 
splenectomy  postpartum.  Worsening  alloimmune 
anaemia also developed in 2 women from Lebanon 
who  required  splenectomy  within  eight  weeks 
postpartum.  Transfusion  was  required  in  35/44 
women  during  pregnancy  (79.5%),  with  27.3% 
requiring transfusion during pregnancy for the first 
time.  The  lowest  mean  Hb  level  was  6.7±2.0  vs. 
8.3±1.2 g/dL in Lebanon and Italy respectively. The 
average ferritin level before pregnancy was 885.2 ± 
658.9 vs.1232.8 ± 902.9 µg/L after pregnancy. In 
total, CS was performed in 48 pregnancies (72.7%), 
the  indications  being  elective  (41.7%),  repeat 
(31.2%)  and  obstetrical  (27.1%).  Pregnancy 
outcome  was  similar  between  Lebanon  and  Italy 
with the exception of a significantly higher rate of 
live births in Italy.
51  
Folic  acid  deficiency  is  common  in  TI  and 
occurs due to poor absorption, low dietary intake, 
or, most significantly, an increased demand for folic 
acid from active bone marrow. This is a particular 
concern  in  pregnancy  since  deficiency  can  cause 
neural  tube  defects,  such  as  spina  bifida,  in  the 
growing foetus. During pregnancy, women with TI 
should  therefore  be given  oral  folic  acid 
supplementation (around 1 mg/day), and should be 
carefully monitored in order to assess the need for 
transfusion  therapy  and  to  avoid  haemodynamic 
compromises.  The  major  fear  of  initiating 
transfusions  during  pregnancy  is  the  development 
of alloantibodies. These can aggravate anaemia and 
progress into severe haemolytic anaemia refractory 
to transfusions and thus increase the complication 
rate. CS may be required in TI patients due to the 
associated cephalopelvic disproportion secondary to 
skeletal  deformity  and  short  stature,  especially  in 
non-transfused  women.  Splenectomy  is  usually 
performed  in  TI  women  for  decreased  levels  of 
haemoglobin,  hyperactivity  of  the  spleen, 
leukopenia and symptomatic thrombocytopenia.
5,6
Management. There  are  a  number  of  options 
currently available for managing patients with TI, 
including  splenectomy,  transfusion  therapy,  iron 
chelation  therapy,  modulation  of  HbF  production 
and haematopoietic stem cell transplantation.
Splenectomy.  As  per  expert  opinion,  the  current 
indications  for  splenectomy  in  TI  include  growth 
retardation  or  poor  health,  leukopenia, 
thrombocytopenia,  increased  transfusion  demand, 
or  symptomatic  splenomegaly.
6 Clinical 
observations,  however,  have  suggested  that 
splenectomy  in  TI  can  contribute  to  an  increased 
susceptibility to TEE and PHT
39,40,43. This calls for a 
review  of  splenectomy  as  a  procedure  of  choice, 
especially with its potential role in increasing TI-
related  complications  and  the  inherent  risk  of 
infection  associated  with  the procedure  even  for 
individuals without haematological disorders.
52
Transfusion and iron chelation therapy. In patients 
with  TM,  a  remarkable  improvement  in  life 
expectancy and  prevention of  morbidity has  been 
achieved  in  recent  decades 
53.  This  is  mainly
attributed  to  improved  methods  of  blood 
transfusion,  better  understanding  of  iron  toxicity, 
and  evolution  in  iron  chelation  therapy.
53 On  the 
other hand, TI has been regarded as a clinical entity 
with  limited  complicationsso  as  the  general 
approach was to avoid early blood transfusions and 
the associated need for chelation therapy. However, 
increasing  evidence  is  delineating  the  benefit  of Medit J Hemat Infect Dis 2009; 1(1); Open Journal System 
transfusion therapy in decreasing the incidence of 
complications as PHT, TEE, and EMH, to name a 
few.
30,39,54 Thus although the common practice was 
to initiate transfusion when complications ensue, it 
may be worthwhile start transfusion therapy earlier 
as  a  preventive  approach  which  will  also  help 
alleviate  the increased  risk  of  alloimmunisation 
with  delayed  initiation  of transfusion.
55 Although 
earlier  introduction  of  blood  transfusions  will 
increase  the  rate  of  iron  accumulation,  effective 
methods  of  iron  chelation  are  now  available 
56,57, 
and  the  benefits  of  transfusion  therapy  would 
greatly outweigh the cost and inconvenience of iron 
chelation therapy. 
The  initiation  of  iron  chelation  therapy  in 
patients with TI depends not only on the amount of 
excess  iron,  but  also  on  the  rate  of  iron 
accumulation,  the  duration  of  exposure  to  excess 
iron and various other factors in individual patients. 
A direct assessment of LIC is recommended, either 
by biopsy or by a non-invasive method such as R2 
MRI.  Where  LIC  measurement  is  not  possible, 
threshold serum ferritin values of 400500 ng/mL 
(which are lower than those generally accepted in 
patients  with  TM)  could  be  considered  as  an 
indicator  for  initiation  of  iron  chelation  therapy. 
Chelation  therapy  should  generally  be  initiated  if 
LIC  exceeds  7  mg/g  dry  weight  of  liver  tissue, 
however  lower  levels  of  LIC  for  initiation  of 
chelation therapy  must  be  considered  particularly 
now with the availability of oral iron chelators.
6
Modulation  of  foetal  haemoglobin  production. 
Increasing the synthesis of HbF can help alleviate 
anaemia and therefore improve the clinical status of 
patients with TI 
58. Production of HbF is reactivated 
during  recovery  from  marrow  suppression  after 
treatment  with  cytotoxic  drugs,  therefore  it  is 
postulated that these agents may alter the pattern of 
erythropoiesis  and  increase  the  expression  of 
gamma-chain genes. Several cytotoxic agents with 
this effect have been identified, including cytosine 
arabinoside  and  hydroxyurea.
59-61 Recently 
published results from Iran, evaluating six years of 
hydroxyurea  therapy  in  transfusion  dependent 
patients  with  TI,  are  encouraging.  A  significant 
decrease  in  the  need  for  blood  transfusions  was 
observed in many patients; the need was completely 
obviated in some patients.
62 Erythropoietin has also 
been shown to increase HbF levels in some patients 
with  TI
58.  Preliminary  trials  with  intravenous  and 
oral butyric acid derivatives have shown increases 
in foetal and total Hb levels in patients with TI,
63-66
and  the  acceptable  safety  profile  of  these  agents 
makes  them  promising  therapeutic  targets.  It  is 
unclear  how  butyrates  stimulate  gamma-globin 
production  or  why  some  patients  respond  to 
treatment while others do not.
However,  the  overall  trial  results  with  HbF-
stimulating  agents  are  somewhat  disappointing. 
Studies  using  combined  treatments  have  shown 
greater promise than the individual agents alone
67. 
Further clinical evaluation is required to clarify the 
value  of  this  approach,  especially  in  view  of  the 
reduced oxygen delivery capacity of HbF, as this 
might  favour  the  implementation  of  a  target  Hb 
level higher than 10 g/dL in response to increased 
need (e.g. PHT, coronary heart disease and chronic 
obstructive  pulmonary  disease  (COPD))  and  an 
increased ratio of HbF/HbA.
Haematopoietic  stem  cell  transplantation. 
Haematopoietic  stem  cell  transplantation  (HSCT), 
where the marrow of an affected patient is replaced 
from  the  stem  cells  of  an  uaffected  donor,  is  an 
established  treatment  for  beta-thalassaemia. 
Although successful HSCT can offer a cure, it can 
be  unsuccessful  (e.g.  if  the  thalassaemia  returns), 
may  lead  to  complications  (e.g.  graft-versus-host 
disease,  growth  impairment,  neurological 
complications), and can even result in death;
68-71the 
risk for a failed transplantation depends primarily 
on the health and age of the patient. The decision as 
to which patients are eligible for transplantation is 
complex and is related to both the quality of life and 
expected survival-time of the transplanted patient, 
when compared with supportive care only. This is 
particularly relevant in patients with TI, especially 
in those who are only mildly affected. Due to the 
risks  involved,  transplantation  is  considered 
appropriate  only  for  patients  with  a  human 
leukocyte  antigen  (HLA)-matched  donor,  which 
comprises  only  30–40%  of  all  beta-thalassaemia 
patients,  at  most.
72 As  HLA  type  is  genetically 
determined,  there  is  a  25%  chance  that  any  two 
siblings will be a match.
Conclusion. Our  understanding  of  the  molecular 
and pathophysiological mechanisms underlying the 
disease process in patients with TI has substantially 
increased over the past decade. Today, a large body 
of  evidence  documents  the  incidence  and 
consequences of the different clinical complications 
associated with the disease. Although there are still 
currently  no  clear  guidelines  for  the  optimal 
management  plan  of  this  disease  entity,  the 
emerging body of evidence looks promising.
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